...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
【24h】

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

机译:新兴病原体念珠菌Auris:生长表型,抗真菌植物,抗真菌,和SCY-078的效果,新型葡聚糖合成抑制剂,对生长形态和生物膜形成

获取原文
获取原文并翻译 | 示例
           

摘要

Candida auris, a new multidrug-resistant Candida spp. which is associated with invasive infection and high rates of mortality, has recently emerged. Here, we determined the virulence factors (germination, adherence, biofilm formation, phospholipase and proteinase production) of 16 C. auris isolates and their susceptibilities to 11 drugs belonging to different antifungal classes, including a novel orally bioavailable 1,3-beta-D-glucan synthesis inhibitor (SCY-078). We also examined the effect of SCY-078 on the growth, ultrastructure, and biofilm-forming abilities of C. auris. Our data showed that while the tested strains did not germinate, they did produce phospholipase and proteinase in a strain-dependent manner and had a significantly reduced ability to adhere and form biofilms compared to that of Candida albicans (P = 0.01). C. auris isolates demonstrated reduced susceptibility to fluconazole and amphotericin B, while, in general, they were susceptible to the remaining drugs tested. SCY-078 had an MIC90 of 1 mg/liter against C. auris and caused complete inhibition of the growth of C. auris and C. albicans. Scanning electron microscopy analysis showed that SCY-078 interrupted C. auris cell division, with the organism forming abnormal fused fungal cells. Additionally, SCY-078 possessed potent antibiofilm activity, wherein treated biofilms demonstrated significantly reduced metabolic activity and a significantly reduced thickness compared to the untreated control (P < 0.05 for both comparisons). Our study shows that C. auris expresses several virulence determinants (albeit to a lesser extent than C. albicans) and is resistant to fluconazole and amphotericin B. SCY-078, the new orally bioavailable antifungal, had potent antifungal/antibiofilm activity against C. auris, indicating that further evaluation of this antifungal is warranted.
机译:Candida Auris,一种新的多药抗性念珠菌SPP。最近出现了与侵袭性感染和高死亡率有关。在这里,我们确定了16℃的毒力因子(萌发,粘附,生物膜形成,磷脂酶和蛋白酶产生)和它们对属于不同抗真菌类的11种药物的敏感性,包括一种新的口服生物可利用的1,3-Beta-D -Glucan合成抑制剂(SCY-078)。我们还研究了SCY-078对C.Auris的生长,超微结构和生物膜形成能力的影响。我们的数据表明,虽然测试的菌株没有发芽,但它们确实以应变依赖性方式产生磷脂酶和蛋白酶,并且与念珠菌蛋白(P = 0.01)相比,粘附和形成生物膜的能力显着降低(P = 0.01)。 C. Auris分离物证明对氟康唑和两性霉素B的易感性降低,而通常,它们易于测试的剩余药物。 SCY-078对C.Auris的MIC90为1毫克/升,并引起完全抑制C.Auris和C. albicans的生长。扫描电子显微镜分析表明,SCY-078中断了C.Auris细胞分裂,与生物体形成异常融合的真菌细胞。另外,SCY-078具有有效的抗抗菌活性,其中处理的生物膜显着降低了代谢活性和与未处理的对照相比显着减少的厚度(P <0.05对于两个比较)。我们的研究表明,C.Auris表达了几种毒力决定因素(尽管众所周知的程度小于C. albicans),并且对氟康唑和两性霉素B.Scy-078,新口服生物可利用的抗真菌剂具有抗性抗真菌/抗菌剂活性。 auris,指示有必要进一步评估这种抗真菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号